Intellia Therapeutics, Inc. cotiza a 11.91 USD y tiene una capitalización bursátil de $1.7B. En los últimos 12 meses ha facturado $60M con un margen de flujo de caja libre del -585.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editin…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.80 | $-0.81 | $-0.83 |
| Estimado | $-0.79 | $-0.78 | $-0.90 | $-0.96 |
| Sorpresa | — | -2.6% | +10.0% | +13.5% |
| Métrica | NTLA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -651.7% | -38.6% | -613.0% |
| Net Margin | -609.9% | -33.6% | -576.3% |
| FCF Margin | -585.0% | -13.9% | -571.1% |
| ROE | -61.5% | -40.4% | -21.1% |
| ROA | -49.0% | -32.0% | -17.0% |
| Current Ratio | 5.08 | 2.84 | +2.24 |
| Debt / Equity | — | 0.28 | — |